Statistics for Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
Total visits
| views | |
|---|---|
| Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose. | 186 |
Total visits per month
| views | |
|---|---|
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 2 |
| November 2025 | 1 |
| December 2025 | 0 |
| January 2026 | 1 |
File Visits
| views | |
|---|---|
| 27_Ribeiro_S_Renal_risk-benefit_determinants_of_recombinant_Clinical_Exp_Pharm_P.pdf | 1 |
Top country views
| views | |
|---|---|
| United States | 118 |
| China | 19 |
| India | 10 |
| Portugal | 7 |
| Ukraine | 7 |
| Brazil | 6 |
| Mongolia | 5 |
| Australia | 3 |
| Poland | 3 |
| Argentina | 2 |
| Japan | 2 |
| Austria | 1 |
| Canada | 1 |
Top city views
| views | |
|---|---|
| Viseu | 2 |
| Chicago | 1 |